148 related articles for article (PubMed ID: 27911011)
1. Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors.
Wang Z; Xu W; Song T; Guo Z; Liu L; Fan Y; Wang A; Zhang Z
Arch Pharm (Weinheim); 2017 Jan; 350(1):. PubMed ID: 27911011
[TBL] [Abstract][Full Text] [Related]
2. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
Xu G; Liu T; Zhou Y; Yang X; Fang H
Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and preliminary biological evaluation of indole-3-carboxylic acid-based skeleton of Bcl-2/Mcl-1 dual inhibitors.
Liu T; Wan Y; Liu R; Ma L; Li M; Fang H
Bioorg Med Chem; 2017 Mar; 25(6):1939-1948. PubMed ID: 28233676
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors.
Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z
Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625
[TBL] [Abstract][Full Text] [Related]
5. Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic.
Zhang Z; Su P; Li X; Song T; Chai G; Yu X; Zhang K
Arch Pharm (Weinheim); 2015 Feb; 348(2):89-99. PubMed ID: 25641608
[TBL] [Abstract][Full Text] [Related]
6. Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors.
Luan S; Ge Q; Chen Y; Dai M; Yang J; Li K; Liu D; Zhao L
Bioorg Med Chem Lett; 2017 May; 27(9):1943-1948. PubMed ID: 28343875
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein.
Lanning ME; Yu W; Yap JL; Chauhan J; Chen L; Whiting E; Pidugu LS; Atkinson T; Bailey H; Li W; Roth BM; Hynicka L; Chesko K; Toth EA; Shapiro P; MacKerell AD; Wilder PT; Fletcher S
Eur J Med Chem; 2016 May; 113():273-92. PubMed ID: 26985630
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.
Pelz NF; Bian Z; Zhao B; Shaw S; Tarr JC; Belmar J; Gregg C; Camper DV; Goodwin CM; Arnold AL; Sensintaffar JL; Friberg A; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2016 Mar; 59(5):2054-66. PubMed ID: 26878343
[TBL] [Abstract][Full Text] [Related]
10. Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
Zhang Z; Liu C; Li X; Song T; Wu Z; Liang X; Zhao Y; Shen X; Chen H
Eur J Med Chem; 2013 Feb; 60():410-20. PubMed ID: 23314054
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.
Shaw S; Bian Z; Zhao B; Tarr JC; Veerasamy N; Jeon KO; Belmar J; Arnold AL; Fogarty SA; Perry E; Sensintaffar JL; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2018 Mar; 61(6):2410-2421. PubMed ID: 29323899
[TBL] [Abstract][Full Text] [Related]
12. 3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
Song T; Li X; Chang X; Liang X; Zhao Y; Wu G; Xie S; Su P; Wu Z; Feng Y; Zhang Z
Bioorg Med Chem; 2013 Jan; 21(1):11-20. PubMed ID: 23206987
[TBL] [Abstract][Full Text] [Related]
13. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.
Burke JP; Bian Z; Shaw S; Zhao B; Goodwin CM; Belmar J; Browning CF; Vigil D; Friberg A; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2015 May; 58(9):3794-805. PubMed ID: 25844895
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
15. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
Tang G; Yang CY; Nikolovska-Coleska Z; Guo J; Qiu S; Wang R; Gao W; Wang G; Stuckey J; Krajewski K; Jiang S; Roller PP; Wang S
J Med Chem; 2007 Apr; 50(8):1723-6. PubMed ID: 17378545
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
17. Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis.
He N; Liu P; Wang Z; Guo Z; Yan X; Chen H; Zhang Z
Biochem Biophys Res Commun; 2019 May; 512(4):921-926. PubMed ID: 30928099
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.
Friberg A; Vigil D; Zhao B; Daniels RN; Burke JP; Garcia-Barrantes PM; Camper D; Chauder BA; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2013 Jan; 56(1):15-30. PubMed ID: 23244564
[TBL] [Abstract][Full Text] [Related]
19. 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.
Abulwerdi FA; Liao C; Mady AS; Gavin J; Shen C; Cierpicki T; Stuckey JA; Showalter HD; Nikolovska-Coleska Z
J Med Chem; 2014 May; 57(10):4111-33. PubMed ID: 24749893
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
